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ABSTRACT: In vitro dissolution tests are performed for new formulations to evaluate in vivo performance, which is affected by the change
of gastrointestinal (GI) physiology, in the GI tract. Thus, those environmental changes should be introduced to an in vitro dissolution test.
Many studies have successfully shown the improvement of in vitro–in vivo correlations (IVIVC) by introducing those physiological changes
into dissolution tests. The gastrointestinal simulator (GIS), a multicompartment in vitro dissolution apparatus, was developed to evaluate
in vivo drug dissolution. A gastric-emptying rate along with transit rate are key factors to evaluate in vivo drug dissolution and, hence,
drug absorption. Dissolution tests with the GIS were performed with Biopharmaceutical Classification System class I drugs at five different
gastric-emptying rates in the fasted state. Computational models were used to determine in vivo gastric-emptying time for propranolol and
metoprolol based on the GIS dissolution results. Those were compared with published clinical data to determine the gastric half-emptying
time. In conclusion, the GIS is a practical tool to assess dissolution properties and can improve IVIVC. C© 2014 Wiley Periodicals, Inc. and
the American Pharmacists Association J Pharm Sci 103:3416–3422, 2014
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models; Transit time; Dissolution rate
INTRODUCTION
Oral dosage forms disintegrate and dissolve in the gastroin-
testinal (GI) tract and are absorbed into the intestinal mem-
brane. The drug concentration at themembrane determines the
local absorption rate. The disintegration and dissolution rates
of oral dosage forms depend on the physicochemical properties
of the compound such as pKa, crystalline energy, solubility, sur-
face area, formulation, as well as the physiological properties
in the GI tract. The Biopharmaceutical Classification System
(BCS) class I and III drugs are highly soluble in the GI tract
and their dissolution rates not likely to be a rate-limiting step in
drug absorption.1 However, BCS class II drugs are categorized
as low solubility and high permeability and the dissolution rate
of BCS class II drugs will likely determine the drug absorption
rate. Therefore, for the formulation development, it would be
valuable for BCS Class II drugs to be able to predict in vivo
performance.
USP dissolution tests apparatus 1 (rotating basket) and 2
(paddle) are routinely used for screening and optimizing for-
mulations and to assure product consistency and quality. Often,
however, the test conditions do not reflect the in vivo environ-
ment of the GI tract. The physiological environment such as
buffer species, buffer capacity, pH, bile salt, liquid volume, and
gastric-emptying rate (motility) are expected to influence in
vivo dissolution that affects the drug absorption.2–5 The incor-
poration of physiologically relevant environmental factors into
an in vitro dissolution apparatuswould likely lead tomore accu-
rate in vivo dissolution predictions. Numerous in vitro dissolu-
tion procedures have been proposed, such as using biorelevant
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media, a two-phase dissolution apparatus, a transfer model,
and also the artificial stomach–duodenum (ASD) apparatus.
Biorelevant media (FaSSGF, FaSSIF, FeSSIF, and bicarbonate
buffers) have been introduced to improve IVIVC as these media
more closely reflect the in vivo lumenal fluid.6–8 As it consists of
both the drug dissolution component (aqueous phase) and the
absorption component (organic phase), the two-phase dissolu-
tion apparatus can provide valuable insight to predict in vivo
performance.9 The transfer model and the ASD can represent
the environmental changes through the GI tract, such as liquid
volume and pH, which can influence the amount of dissolved
drug.
Kostewicz et al.10 utilized the transfer model for poorly sol-
uble weak base drugs to predict in vivo precipitation rate with
changing transit rate from the stomach to the duodenum. The
precipitation rates in in vitro tests were evaluated in the fasted
and the fed states. On the basis of these results, the trans-
fer model better represented in vivo performance for the drugs
studied. Carino and coworkers11,12 developed the ASD appara-
tus that is the two-compartment dissolution system consisting
of chambers representing the stomach and duodenum. ASD dis-
solution tests of carbamazepine were performed to understand
in vivo dissolution of different crystal forms of carbamazepine
in the fasted and the fed states. The ASD accurately predicted
drug absorption in dogs for the different crystal forms. The ASD
system has successfully demonstrated in vivo phenomena and,
therefore, supports the usefulness of the two-compartment dis-
solution system to improve IVIVC.
Because the residence time in the human jejunum and ileum
is much longer than the transit time of the human duodenum
(∼30 min), most drugs will be absorbed along the small intes-
tine. Thus, drug concentration in the jejunal chamber, rather
than simply in the duodenal chamber alone, was considered im-
portant for in vitro dissolution to predict drug absorption.13,14
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Weak basic drugs, for example, will bemore readily dissolved
in the acidic condition and then may precipitate or remain
as a supersaturated solution upon entering the duodenum be-
cause of the higher lumenal pH.15,16 Supersaturation will likely
enhance the bioavailability of lipophilic weak basic drugs.17,18
The supersaturation and precipitation rate will be affected by
the transit rate, because of the changes of drug concentration,
buffer capacity, and pH that occur in association with the tran-
sit rate. Hence, the determination of transit rate from the gas-
tric chamber to the duodenal chamber is an important factor in
themulticompartment dissolution apparatus for the evaluation
of in vivo dissolution.
In this study, we developed an apparatus called gastroin-
testinal simulator (GIS), based on the ASD system of Carino
and coworkers,11,12 which consists of the gastric, duodenal, and
jejunal chamber, and we determined the gastric-emptying time
and transit time required to simulate in vivo performance of
propranolol and metoprolol. The dissolution tests of propra-
nolol and metoprolol were performed with the GIS at five dif-
ferent transfer rates representing the gastric-emptying rate.
The predicted pharmacokinetics parameters were obtained by
GastroPlusTM based on dissolution results. Those results were
compared with the clinical data to determine the appropriate
transfer rate needed to best simulate the gastric half-emptying
time in the GIS. This system may be able to perform better
IVIVC by monitoring the dissolution rate, the dissolved drug
concentration, and the potential measurement of drug precipi-
tation and supersaturation in these chambers.
MATERIALS AND METHODS
Materials
Metoprolol tablets (100 mg) and propranolol tablets
(40mg) were obtained from Ingenus Pharmaceuticals (Orlando,
Florida) and PLIVA (Sarajevo, Bosnia and Herzegovina), re-
spectively. Metoprolol tartrate, propranolol hydrochloride, hy-
drochloric acid, sodium phosphate dibasic, and sodium chlo-
ride were obtained from Sigma–Aldrich Chemical Company
(St. Louis, Missouri). Orthophosphoric acid 85%, trifluoroacetic
acid, methanol, and acetonitrile were obtained from Fisher Sci-
entific Inc. (Pittsburgh, Pennsylvania). All chemicals were of
analytical grade or of HPLC grade.
Gastrointestinal Simulator
The diagram of the GIS is shown in Figure 1a and consists of
three dissolution chambers representing the stomach, the duo-
denum, and the jejunum. Four precision pumps are utilized to
simulate gastric fluid secretion, duodenal fluid secretion, trans-
fer of gastric chamber contents to the duodenal chamber, and
also to transfer duodenal contents to the jejunal chamber. All
pump speeds can be adjusted. The gastric and duodenal fluids
weremaintained at 37◦C in the water bath, and pH probes were
placed in the gastric and duodenal chambers to monitor pH at
60 s intervals. The paddles in the gastric and duodenal cham-
bers were appropriately controlled to simulate relevant gastric
and duodenal motility. The jejunal chamber was stirred at a
Figure 1. The diagram of GIS (a). The GIS dissolution model (b).
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constant speed. Samples were taken from each chamber at a
specific time, and supernatant was diluted with H2O–methanol
(1/1, v/v) after centrifugation (2000g, 20 s). Dissolved drug con-
centration was determined by HPLC analysis.
GIS Condition, Process, and Theory
The GIS system was designed to represent the physiologi-
cal conditions of the human GI tract in the fasted state. The
test conditions were as follows. The gastric chamber was filled
with 50 mL of 0.01 N HCl to represent the gastric fluid and
250 mL of water to represent the dose volume. The duode-
nal chamber was filled with 50 mL of 0.05 M sodium phos-
phate buffer (pH 6.5) to represent duodenal fluid, and the jeju-
nal chamber was left empty. During dissolution testing, simu-
lated gastric fluid (0.01 N HCl) and simulated duodenal fluid
(0.1 M sodium phosphate buffer, pH 6.5) were pumped into
each chamber at 1 mL/min. The tablet was placed into the gas-
tric chamber to start the dissolution test. The gastric contents,
both dissolved and undissolved material, were moved to the
duodenal chamber at the first-order rate that could be set to
any value as the gastric half-emptying time. Additionally, the
duodenal contents were moved to the jejunal chamber with the
same rate as the gastric half-emptying rate and the duodenal
fluid secretion rate. The fluid volume in the duodenal chamber
thus was maintained at 50 mL during dissolution testing.
Figure 1b shows the various dynamic processes in the GIS
chambers. The test tablet is introduced into the gastric cham-
ber where disintegration can occur. Immediate-release dosage
forms are expected to disintegrate and potentially dissolve to
some extent in the gastric chamber. However, dissolved drug
may be precipitated in the gastric chamber depending on the
physicochemical properties of the drug. The dissolved drugs,
solid drug particles, and excipients present in the gastric cham-
ber are transferred to the duodenal chamber. Themathematical
models representing these processes are shown in Eqs. (1) and
(2) as follows:
dMsd,s
dt
= −kd,sMsd,s − ksd,s−dMsd,s + kp,sMsl,s (1)
dMsl,s
dt
= kd,sMsd,s − ksl,s−dMsl,s − kp,sMsl,s (2)
where Msd,s and Msl,s are the amounts of solid drug (sd) and
dissolved drug in solution (sl) in the gastric chamber, kd,s and
kp,s are the dissolution rate constant and the precipitation rate
constant in the gastric chamber, respectively. The transfer rate
constants for solid drug and solution drug from the gastric
chamber to the duodenal chamber are ksd,s–d and ksl,s–d. The
expressions for dissolution and precipitation rates are approx-
imate mathematical expressions, included here for more sym-
bolic purposes. They assume constant, first-order processes that
are not affected by factors such as drug saturation solubility or
variable pH in the bulk fluid and at the surface of the drug
particles. These approximations are likely suitable for this par-
ticular study, because of the high solubility of propranolol and
metoprolol. The development of mechanistic models for disso-
lution and precipitation rates in the GIS system was not within
the scope of the current study.
In the duodenal chamber, weak acid drugs might be dis-
solved, whereas dissolved weak basic drugs might be precip-
itated. In the jejunal chamber, dissolution and precipitation
proceed depending on the physicochemical properties of drugs.
The amount of solid drug and dissolved drug in the duodenum
and jejunum chamber is shown in Eqs. (3)–(6) as follows:
(Duodenal chamber)
dMsd,d
dt
= ksd,s−dMsd,s − kd,dMsd,d − ksd,d−jMsd,d + kp,dMsl,d (3)
dMsl,d
dt
= ksl,s−dMsl,s + kd,dMsd,d − ksl,d−jMsl,d − kp,dMsl,d (4)
(Jejunal chamber)
dMsd,j
dt
= ksd,d−jMsd,d − kd,jMsd,j + kp,jMsl,j (5)
dMsl,j
dt
= ksl,d−jMsl,d + kd,jMsd,j − kp,jMsl,j (6)
whereMsd,d,Msl,d,Msd,j, andMsl,j are the amounts of solid drug
and dissolved drug in the duodenal and jejunal chambers, re-
spectively. kd,d, kp,d, kd,j, and kp,j are the dissolution rate con-
stants and the precipitation rate constants in the duodenal
and jejunal chambers, respectively. The transfer rate constants
for solid drug and dissolved drug from the duodenal chamber
to the jejunal chamber are ksd,d–j and ksl,d–j.
In this study, the GIS was used with five different
gastric half-emptying times (t1/2 = 5, 10, 15, 20, and
30 min). Oral drug absorption and pharmacokinetics param-
eters were predicted by GastroPlusTM (version 6.0; Simulation-
Plus, Inc., Lancaster, California). The pharmacokinetics pa-
rameters (Cmax, Tmax, and AUC) between clinical data and in
silico results were then compared to determine the gastric half-
emptying time in the GIS that best simulated in vivo results.
GastroPlus
TM
Simulation
The physicochemical and biopharmaceutical properties of pro-
pranolol and metoprolol used in the GastroPlusTM prediction
are presented in Table 1.19–26 The dissolution profiles with the
GIS were created by adding together the dissolved drug in both
the duodenal and jejunal chambers. The absorption was pre-
dicted by GastroPlusTM with those dissolution profiles for pro-
pranolol and metoprolol. No drug absorption from the stomach
was assumed in this set of predictions, and the dosage form
drug release was simulated as a controlled-release tablet in the
GastroPlusTM based on the dissolution profiles of propranolol
and metoprolol obtained with the GIS (Figs. 2e and 4e). Virtual
trials were performed (n = 100) on each gastric half-emptying
time to obtain plasma concentration curves and pharmacoki-
netics parameters.
RESULTS
Propranolol
Figures 2a and 2b present the mean dissolved drug
concentration–time profiles in each chamber with the fastest
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Table 1. Chemical/Physiological/Pharmacological Parameters of
Propranolol and Metoprolol for GastroPlus
TM
Simulation
Propranolol Metoprolol
MW 259.3 267.4
Dose (mg) 80a 100a
Dose volume (mL) 250 250
Solubility (mg/mL) 33b 16.9c
log P 2.65d 1.72d
pKa 9.5e 9.7b
Human Peff (×10−4 cm2/s) 2.9d 1.5a
Body weight (kg) 70 70
Vc (L/kg) 4.2f 5.2g
Total clearance (L/h) 65h 83g
Vc, volume of central compartment;
aRef. 19.
bRef. 20.
cRef. 21.
dRef. 22.
eRef. 23.
fRef. 24.
gRef. 25.
hRef. 26.
and slowest gastric half-emptying times, 5 or 30 min, in this set
of experiments. Two 40mg propranolol tablets (maximum dose,
80 mg) were placed into the gastric chamber to start the GIS
dissolution study.Maximumdissolved drug concentration (cmax)
in each chamber was influenced by the gastric half-emptying
time and transit time; cmax ratios between 5 and 30 min gastric
half-emptying time (cmax 5 min/cmax 30 min) were increased by
15.5% (the gastric chamber), 30.2% (the duodenal chamber),
and 13.4% (the jejunal chamber).
Figures 2c and 2d present the mean dissolved drug (%)–time
profiles in each chamber with the fastest and slowest gastric
half-emptying times, 5 or 30 min, in this set of experiments.
Comparing the results of the GIS dissolution tests between 5
and 30 min gastric half-emptying time, the time of maximum
dissolved drug (tmax) was delayed from 2.5 to 5min in the gastric
chamber, and from 12.5 to 25 min in the duodenal chamber.
After achieving tmax in respective chambers, the amounts of
dissolved drug were steadily decreased as the contents were
transferred to the next chamber. In contrast, the amounts of the
dissolved drug in the jejunal chamber were steadily increased
because of transfer from the duodenal chamber.
With five different gastric half-emptying times, the sum of
the dissolved drug in the duodenal and jejunal chambers was
calculated as shown in Figure 2e. The gastric half-emptying
time influenced the drug amount in the duodenal and jejunal
chambers. However, the gastric half-emptying time did not in-
fluence the dissolution rate of propranolol tablets, which were
completely dissolved within 7.5 min (Fig. 2f).
Figure 3 shows that the predicted oral absorption of pro-
pranolol by GastroPlusTM using the dissolution profiles from
the GIS along with human clinical data. Shifts in the plasma
Figure 3. Comparison of plasma concentration–time profiles for pro-
pranolol tablets between predicted data by GastroPlus
TM
and clinical
data from Eddington et al.27
Figure 2. The dissolved drug concentration–time profiles of propranolol in the gastric, duodenal, and jejunal chambers with the fastest and
slowest gastric half-emptying time: 5 (a) and 30min (b). Dissolved drug–time profiles of propranolol in the gastric, duodenal, and jejunal chambers
with 5 (c) and 30 min (d). The sum of dissolved drug–time profiles of propranolol in the duodenal and jejunal chambers (e). The sum of dissolved
drug–time profiles of propranolol in the gastric, duodenal, and jejunal chambers (f). Each data point represents mean ± SD (n = 3).
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Table 2. Mean Pharmacokinetics Parameters for Propranolol and Metoprolol Simulated by GastroPlus
TM
Gastric Half-Emptying Time Propranolol Metoprolol
(t1/2, min) Cmax (ng/mL) Tmax (h) AUC∞ (ng h/mL) Cmax (ng/mL) Tmax (h) AUC∞ (ng h/mL)
5 110.8 2.0 858.6 89.6 1.5 421.5
10 98.6 2.5 827.3 79.5 2.0 424.5
15 91.4 3.0 824.4 69.1 2.5 402.0
20 81.0 3.5 803.0 60.7 3.1 388.3
30 70.9 4.1 779.1 50.0 3.9 374.7
Clinical data 109.5a 2.1a 821.6a 89.4b 1.6b 444.6b
aRef. 27.
bRef. 28.
Virtual trials (n = 100).
concentration–time curves were observed because of slow gas-
tric half-emptying time. The plasma concentration–time pro-
file with 5 min gastric half-emptying time displayed a plasma
concentration curve very similar to clinical data. These results
indicate that the gastric half-emptying time in the GIS should
be between 5 and 10 min (Table 2).
Metoprolol
Figures 4a and 4b present the mean dissolved drug
concentration-time profiles in each chamber with the fastest
and slowest gastric half-emptying times, 5 or 30 min, in this set
of experiments. One 100 mg metoprolol tablet (maximum dose,
100 mg) was placed into the gastric chamber to start the GIS
dissolution study. The cmax in each chamber was influenced by
the gastric half-emptying time and transit time; cmax ratios be-
tween 5 and 30 min gastric half-emptying time (cmax 5 min/cmax
30 min) were increased by 148% and 92.3% in the gastric and
duodenal chambers, but were decreased by 6.3% in the jejunal
chamber.
Figures 4c and 4d present the mean dissolved drug (%)–time
profiles in each chamber with the fastest and slowest gastric
half-emptying times, 5 or 30 min, in this set of experiments.
Comparing the results of the GIS dissolution tests between 5
and 30 min gastric half-emptying time, tmax was delayed from
12.5 to 15 min in the gastric chamber, and from 25 to 30 min in
the duodenal chamber. After achieving tmax in both chambers,
the amounts of dissolved drug were steadily decreased as the
contents were transferred to the next chamber. In contrast, the
amount of the dissolved drug in the jejunal chamber steadily
increased because of transfer from the duodenal chamber.
With five different gastric half-emptying times, the sum of
the dissolved drug in the duodenal and jejunal chambers was
calculated as shown in Figure 4e. The gastric half-emptying
time influenced the drug amount in the duodenal and jejunal
chambers. However, the gastric half-emptying time did not in-
fluence the dissolution rate of metoprolol tablets, which were
completely dissolved within 20 min (Fig. 4f).
Figure 5 shows that the predicted oral absorption of meto-
prolol by GastroPlusTM using the dissolution profiles from
the GIS along with human clinical data. Shifts of plasma
concentration–time curves were observed because of slow gas-
tric half-emptying time. Plasma concentration–time profile
Figure 4. The dissolved drug concentration–time profiles of metoprolol in the gastric, duodenal, and jejunal chambers with the fastest and
sowest gastric half-emptying time: 5 (a) and 30 min (b). Dissolved drug–time profiles of metoprolol in the gastric, duodenal, and jejunal chambers
with 5 (c) and 30 min (D). The sum of dissolved drug–time profiles of metoprolol in the duodenal and jejunal chambers (e). The sum of dissolved
drug–time profiles of metoprolol in the gastric, duodenal, and jejunal chambers (f). Each data point represents mean ± SD (n = 3).
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Figure 5. Comparison of plasma concentration–time profiles for
metoprolol tablets between predicted data by GastroPlus
TM
and clinical
data from Rekhi et al.28
with 5min gastric half-emptying time displayed similar plasma
concentration curves to clinical data. These results are consis-
tent with those observed for propranolol (Table 2).
DISCUSSION
The gastric-emptying time and the transit time in the GI tract
are important factors to predict in vivo dissolution because the
gastric-emptying time can affect fluid volume in stomach and
the transit time can affect drug dissolution and drug absorption
in the small intestine. However, most in vitro dissolution ap-
paratuses do not consider gastric-emptying time and intestinal
transit or residence time. The incorporation of these factors into
an in vitro dissolution apparatus can lead to better predictions
of in vivo dissolution. Therefore, it is necessary to develop a
dissolution apparatus, the GIS, to simulate gastric emptying to
predict better in vivo dissolution. In the human fasted state, it
has been reported that liquids gastric half-emptying time was
4.2,29 12,30 and 15.8 min.31 In this set of dissolution studies,
five different gastric emptying half-times (5, 10, 15, 20, and 30
min) were tested with the GIS, and pharmacokinetics param-
eters were obtained by GastroPlusTM based on the dissolution
results with the GIS. Those pharmacokinetics parameters were
compared with human clinical data.
As propranolol and metoprolol are highly soluble over the
physiological pH range and also highly permeable in the entire
small intestine, it is likely that gastric-emptying rate itself is
the rate-limiting step to appearance of drug in the bloodstream.
As shown in Figures 2f (propranolol) and 4f (metoprolol), total
dissolution rate in the entire GIS system was not influenced
by gastric emptying or transit rate because both drugs are of
high solubility. However, the appearance of dissolved drug in
the duodenal and jejunal chambers was delayed for both drugs
with an increase in gastric-emptying half-time, which can be
attributed simply to the slower gastric emptying.
Although direct comparison of experimental and predicted
results requires direct measurement of drug concentrations in
solution in the intestinal fluid, a qualitative comparison can
be made based on average plasma levels in the literature. The
comparison of pharmacokinetics parameters and plasma con-
centration curves between human clinical data and in silico
data can suggest the suitable transit time for the GIS to pre-
dict in vivo dissolution. In silico software revealed that the
time of maximum plasma concentration (Tmax) and maximum
plasma concentration (Cmax) were influenced by the gastric half-
emptying time. By comparing these pharmacokinetics param-
eters with human clinical data, the gastric half-emptying time
between 5 and 10 min for the GIS studies provided a good
match to human in vivo systemic availability (and presumably
the luminal fluid dissolution) in the fasted state (Figs. 3 and
5; Table 2). This relatively rapid estimate of gastric emptying
time using the GastroPlusTM simulation for these rapidly dis-
integrating and dissolving IR dosage forms is consistent with
one study that indicated a more rapid emptying of liquids from
the stomach.29 However, it is shorter than other measurements
indicating a gastric half-emptying time of about 15 min.13
In this study, dissolution tests with the GIS were performed
for propranolol and metoprolol. Propranolol and metoprolol ex-
hibited different times for complete dissolution (propranolol:
7.5 min; metoprolol: 20 min) (Figs. 2f and 4f). With a gastric
half-emptying time of 5 min, this difference clearly influenced
drug concentration in each chamber, but this difference did
not influence drug concentration in the duodenal and jejunal
chamber with a gastric half-emptying time of 30 min (Figs. 2
and 4). Comparing the concentration profiles (cmax concentra-
tion/dose ratio) between propranolol and metoprolol with the
gastric half-emptying time at 5 min, metoprolol exhibited 126%
and 57% higher cmax in the gastric and duodenal chambers than
propranolol. However, metoprolol exhibited 26% lower cmax in
the jejunal chamber than propranolol. Furthermore, compar-
ing tmax between propranolol and metoprolol with the gastric
emptying time at 5 min, a tmax difference was observed in each
chamber, propranolol (2.5 min) versus metoprolol (12.5 min) in
the gastric chamber, and propranolol (12.5 min) versus meto-
prolol (25 min) in the duodenal chamber. As these results show,
the GIS can evaluate disintegration time and dissolution rate
in each chamber depending on test drugs. However, the short
gastric-emptying time suggested requiring further direct mea-
surement in the luminal intestinal fluid.
The GIS can not only assess cmax and tmax, but can also eval-
uate the in vivo dissolution profile. For example, Carino et al.11
performed the ASD, of which the GIS is an adaption with a jeju-
nal compartment, to estimate bioavailability of carbamazepine
(BCS class II drug) that has three different crystal forms. Dis-
solution profiles of different carbamazepine crystal forms in the
duodenal chamber were compared with oral bioavailability of
those crystal forms in dogs. The results showed an excellent cor-
relation between the ASD dissolution results and dog bioavail-
ability. For BCS class II weak basic drugs, the precipitation
rate and supersaturation in the GI tract will significantly af-
fect oral bioavailability. The GIS allows these phenomena in the
duodenal and jejunal chambers to be observed and measured,
in a less complex environment than the luminal intestinal fluid,
and can provide valuable information with which to predict in
vivo dissolution. Thus, the GIS appears to be a very useful tool
for the development of oral drug formulations.
CONCLUSION
The dissolution results with the GIS system provide a conve-
nient means of quantitating drug concentration in the cham-
bers representing the stomach, duodenum, and jejunum that
directly impact in vivo drug absorption. This in vitro GI com-
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partment concentration is the information needed for the pre-
diction of oral drug absorption. The gastric half-emptying time
in the fasted state was determined in these studies as a part
of the GIS development. This is a significant factor for a multi-
compartment dissolution apparatus in the prediction of in vivo
dissolution. In this study, the gastric half-emptying time for the
GISwas observed to be between 5 and 10min, and although it is
in general agreement with previous reports of the gastric emp-
tying of liquids,29,30 it is shorter than other reported value.13
This requires direct confirmation by measuring luminal fluid
concentrations in the future.
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